comparemela.com

Latest Breaking News On - Oncopeptides pepaxti - Page 1 : comparemela.com

European Commission approves Oncopeptides Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

/PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat.

United kingdomOncopeptides pepaxtiRolf gulliksenJakob lindbergOncopeptide pepaxtiEuropean commissionGlobal head of corporate communicationsNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsMultiple myelomaMid capOncopeptides ab

European Commission approves Oncopeptides Pepaxti for the treatment of patients with relapsed refractory multiple myelo

(Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for.

United kingdomOncopeptides pepaxtiRolf gulliksenJakob lindbergEuropean commissionGlobal head of corporate communicationsNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsMid cap

Oncopeptides AB: European Commission approves Oncopeptides Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

STOCKHOLM, Aug. 18, 2022 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological

United kingdomOncopeptides pepaxtiRolf gulliksenJakob lindbergOncopeptide pepaxtiEuropean commissionGlobal head of corporate communicationsNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsMid cap

European Commission approves Oncopeptides Pepaxti for the treatment of patients with relapsed refractory multiple myeloma | Small Molecules

European Commission approves Oncopeptides Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

United kingdomOncopeptides pepaxtiRolf gulliksenJakob lindbergOncopeptide pepaxtiEuropean commissionGlobal head of corporate communicationsSwedeni augustNasdaq stockholmEuropean economic areaGlobal headCorporate communicationsMultiple myelomaMid capSmall moleculeNew chemical entity

Oncopeptides publishes Q2 report 2022 - Press Release

STOCKHOLM, Aug. 11, 2022 /PRNewswire/ Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a biotech company focused on research and development of the

United kingdomOncopeptides pepaxtiAnnika muskantorRolf gulliksenKlaas bakkerJakob lindbergCommittee for medicinal products humanOncologic drugs advisory committeeEuropean commissionEuropean medicines agencyGlobal head of corporate communicationsMedicinal productsHuman useGlobal headCorporate communicationsSwedish financial instruments trading act

vimarsana © 2020. All Rights Reserved.